Home » News » Awards & Advancement » Eurofins AvTech Names New President

Eurofins AvTech Names New President

Thursday, September 11, 2008

Eurofins AvTech Laboratories, a Portage, MI-based contract research organization (CRO), has appointed three senior-level executives to its management team. Dr. Raymond Farmen was named president. Farmen is responsible for general management, technical and profit/loss decisions for the company. He also will provide technical and scientific direction for method development, bioanalytical, product testing and animal health areas. In addition to Farmen, Dr. Steven Weber has joined AvTech’s senior management team as director, Bioanalytical, and Leon Clark, Jr. is director, Animal Health.

In other personnel moves in the clinical trials industry:

Greenwich, Conn.-based CRO Aptuit has named Thierry Amat chief financial officer, overseeing the company’s financial and information technology departments. Amat most recently served as CFO of Sodexho, a publicly traded food services company. Amat’s appointment comes less than a month after the CRO named Timothy C. Tyson executive chairman and acting CEO, following the retirement of founding CEO Michael A. Griffith.

ICON Central Laboratories, a division of Dublin, Ireland-based CRO ICON, has named Dr. Guy Dewil chief operating officer (COO) in an effort to further enhance its global capabilities. Dewil will oversee ICON Central Laboratories’ global operations, encompassing facilities in New York, Ireland, and Singapore. Before joining ICON, Dewil was COO at BARC Global Central Laboratories.

Patient enrollment firm Integrated Clinical Trial Services (ICTS) named Dr. David M. Shearer chief medical officer and vice president of clinical operations. Shearer will oversee the medical components of ICTS-affiliated clinical trials by providing protocol review, quality assurance in patient recruitment, and physician education. Before joining ICTS, Shearer held various clinical management positions at several large pharmaceutical companies including GlaxoSmithKline, Wyeth, and Sanofi-Aventis.

Related Posts